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Abstract Links between infective endocarditis (IE) and den-
tal and other invasive procedures were first identified in the
1920s, and the use of antibiotic prophylaxis (AP) to prevent IE
was first recommended by the American Heart Association in
1955. Recognising the weak evidence to support this practice
and the wider risks of anaphylaxis and antibiotic resistance,
guidelines in the USA and Europe have been rationalised in
the last decade with restriction of AP to those patients per-
ceived to be at the highest risk. In the UK, the National
Institute for Health and Care Excellence controversially rec-
ommended the complete cessation of AP for all invasive pro-
cedures in 2008 and subsequent epidemiological studies have
suggested a significant increase in cases above the baseline
trend. AP appears to be safe and is likely to be cost-effective.
Until further data are available, we recommend continued ad-
herence to US and European guidelines.
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Introduction
Infective endocarditis (IE) is an infection of the endocardium
(particularly the valve leaflets) with a yearly incidence of 3–10
per 100,000 [1–3] and is characterised by the development of
infected heart valve vegetations. Prognosis is poor with an in-
hospital mortality of 15-20%, rising to approximately 30% at
1 year [1–3]. Prolonged high-dose intravenous antibiotics are
the mainstay of treatment, but surgery (valve repair or replace-
ment) is required in 40–50% of cases [1–3]. Morbidity is high
in those who survive, with a significant risk of re-infection or
relapse, as well as progressive deterioration in valve function
leading to heart failure and the need for further medical and
surgical intervention [1–3].With such highmortality and mor-
bidity, prevention strategies have always been a priority.
Historical Background
The first suggestion that IE might be caused by microorgan-
isms came from Winge in 1870 [4]. Klebs [5] and others
confirmed that IE was an infectious disease, and experiments
by Rosenbach [6], Wyssokowitsch [7] and others in the late
1800s established that bacteria entering the circulation could
colonise damaged heart valves. Osler identified the impor-
tance of fibrin and platelet deposition on damaged endocardi-
um and the primary role of microorganisms in pathogenesis
[8–10]. However, the concept that bacteria released into the
circulation during invasive dental procedures might cause IE
was first suggested by Lewis and Grant in 1923 [11] and
confirmed in 1935 byOkell and Elliott [12] who demonstrated
that 61% of patients following dental extraction had a positive
blood culture for oral viridans group Streptococci and that oral
viridans group Streptococci could be isolated from the vege-
tations of 40–45% of IE cases.
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These observations occurred during a period when the fo-
cal infection hypothesis implicated oropharyngeal sepsis as
the cause of many systemic diseases [13, 14] leading to the
systematic removal of teeth and other tissues in an attempt to
prevent conditions such as IE. Following a critical appraisal of
the focal infection hypothesis by Reinmann and Havens in
1940, this practice gradually drew to a close [15, 16].
The antimicrobial effects of sulphonamides were first
recognised in the 1930s. This was soon followed by the
suggestion that their use as antibiotic prophylaxis (AP)
could reduce the risk of IE in patients with rheumatic
heart disease undergoing invasive dental procedures
[17–19]. Hirsch et al. [20] subsequently demonstrated
reduced streptococcal bacteraemia in a group receiving
penicillin prophylaxis compared to controls, paving the
way for the American Heart Association (AHA) to pro-
duce the first official guidelines on the use of AP in
1955 [21].
Initial Guidelines on the Use of Antibiotic
Prophylaxis to Prevent IE
The first AHA guidelines identified those with rheumatic or
congenital heart disease as being at increased risk of IE, and
“dental extraction and other dental manipulations which dis-
turb the gums, the removal of tonsils and adenoids, the deliv-
ery of pregnant women, and operations on the gastrointestinal
or urinary tracts” as procedures where APwas indicated. They
recommended intramuscular penicillin (600,000 units of
aqueous penicillin or 500,000 units of procaine penicillin in
oil containing 2% aluminium monostearate) 30 min before
dental procedures. An alternative, but less desirable, oral pen-
icillin regimen was also described (250,000–500,000 units
“one-half hour before each meal and at bedtime, beginning
twenty-four hours prior to the operation and continuing for 5
days”, an extra dose of 250,000 units being desirable at the
time of the procedure).
Over the next two decades, there were four further itera-
tions of the AHA guidelines [22–25]. During this period, the
recommendation that women should receive AP during child-
birth was dropped. However, the emergence of valve replace-
ment surgery during the 1960s and 1970s [26–29] brought
recognition that these patients were at particularly high-risk
of IE. As a result, the 1975 guidelines recommended that these
patients receive an AP regimen consisting of intramuscular
streptomycin (1 g) plus intramuscular penicillin (1,000,000
units of aqueous penicillin G or 600,000 units of procaine
penicillin G), whilst other at-risk patients were recommended
intramuscular penicillin alone or in combination with strepto-
mycin. Importantly, the possibility that bacteraemia with oral
organisms could occur in the absence of dental procedures and
the consequent need to “maintain the highest level of oral
health” were recognised for the first time.
The Move Towards Single Oral Dose Antibiotic
Prophylaxis Regimens
In 1982, the British Society for Antimicrobial Chemotherapy
(BSAC) produced the first UK guidelines [30]. The main dif-
ference between these and the 1977 AHA guidelines was a
shift away from complex parenteral or multi-dose oral AP
regimens, as these had been associated with poor compliance
by dentists [31]. Instead, a single 3 g oral dose of amoxicillin
1 hour before the procedure was recommended on the grounds
of effectiveness and improved compliance. Furthermore, the
same protocol was recommended for all patients at increased
risk of IE, including those with prosthetic valves. Parenteral
antibiotic regimens were only recommended for those under-
going a general anaesthetic. Subsequent AHA and ESC guide-
lines moved towards wider adoption of simple oral AP regi-
mens and the adoption of clindamycin in preference to eryth-
romycin for those allergic to penicillins.
Following an IE symposium in Lyon in 1993, an interna-
tional group of experts reviewed all guidelines (French,
German, Dutch, Scandinavian, UK, and US) and published
proposals for European consensus [32]. They categorised pa-
tients at high risk of IE (those with prosthetic valves, congen-
ital heart disease causing cyanosis and previous IE) or lower-
risk (those with valvular heart disease, including mitral valve
prolapse with regurgitation and bicuspid aortic valve), and
provided a list of cardiac conditions not-at-risk for IE. They
highlighted the need for AP prior to invasive dental proce-
dures associated with gingival bleeding, tonsillectomy,
adenoidectomy and some gastrointestinal and urological pro-
cedures but indicated there was little evidence to support a risk
of IE with endotracheal intubation, fiberoptic procedures, col-
poscopy, vaginal hysterectomy or vaginal delivery.
The 1997 AHA guidelines divided patients into high-risk,
moderate-risk and negligible-risk categories [33]. There was
close agreement with the European Consensus guidelines
[32], although surgically constructed systemic pulmonary
shunts and conduits were added to the high-risk category.
Dental and other procedures that should and should not be
covered with AP were also more clearly defined. For the first
time, the AHA guidelines recommended a single 2 g oral dose
of amoxicillin as the preferred AP regimen for all patients at
risk of IE undergoing dental, oral, respiratory tract or oesoph-
ageal procedures, with clindamycin 600 mg as a single oral
dose 1 h before the procedure for those allergic to penicillin.
These guidelines were broadly matched by the 2004 European
Society of Cardiology (ESC) guidelines [34] so that most
international guidelines were closely aligned.
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Table 1 Current guidelines on antibiotic prophylaxis to prevent infective endocarditis (IE)
2007 AHA Guidelines 2015 ESC Guidelines 2015 NICE Guidelines with 
2016 Amendment
Those Recommended for Antibiotic Prophylaxis Cover
Those at highest risk of an adverse 
outcome from IE
Those at highest risk of IE
undergoing a high-risk procedure
Antibiotic prophylaxis against 
infective endocarditis is not 
recommended routinely for people 
undergoing dental [or other] 
procedures. (‘routinely’ added 2016)
Those at Highest Risk of 
Adverse Outcome from IE 
Those at Highest-Risk of IE Those At Risk of Developing 
IE
Prosthetic cardiac valve or 
prosthetic material used for valve 
repair
Previous IE
Unrepaired cyanotic CHD, 
including palliative shunts and 
conduits
Completely repaired congenital 
heart defect with prosthetic 
material or device, whether 
placed by surgery or catheter 
intervention during the first 6 
months after the procedure
Repaired CHD with residual 
defects at the site or adjacent to 
the site of a prosthetic patch
Cardiac transplantation recipients 
who develop valvulopathy
Patients with any prosthetic valve, 
including a transcatheter valve, or 
those in whom any prosthetic 
material was used for cardiac 
valve repair
Patients with a previous episode 
of IE
Any type of cyanotic CHD
Any type of CHD repaired with a 
prosthetic material, whether 
placed surgically or by 
percutaneous techniques, up to 6 
months after the procedure or 
lifelong if residual shunt or valvular 
regurgitation remains after the 
procedure
Acquired valvular heart disease 
with stenosis or regurgitation 
Valve replacement 
Structural congenital heart 
disease, including surgically 
corrected or palliated structural 
conditions, but excluding isolated 
atrial septal defect, fully repaired 
ventricular septal defect or fully 
repaired patent ductus arteriosus, 
and closure devices that are 
judged to be endothelialised 
Previous infective endocarditis 
Hypertrophic cardiomyopathy. 
Moderate/Intermediate-Risk
Patients with a previous history of 
rheumatic fever
Patients with any other form of 
native valve disease (including: 
bicuspid aortic valve, MVP and 
calcific aortic stenosis)
Patients with unrepaired 
congenital anomalies of the heart 
valves
High-Risk Procedures for which Antibiotic Prophylaxis Should Be Considered
All dental procedures that involve 
manipulation of the gingival 
tissue or the periapical region of 
teeth or perforation of the oral 
mucosa*.
Procedures on respiratory tract 
or infected skin, skin structures 
or musculoskeletal tissue.
Antibiotic prophylaxis should only 
be considered for dental 
procedures requiring manipulation 
of the gingival or periapical region 
of the teeth or perforation of the 
oral mucosa*.
Advice not given 
Recommended Antibiotic Prophylaxis Regimen (for those not allergic to penicillin)
Amoxicillin 2g orally 30-60 mins 
before the procedure**
Amoxicillin 2g orally 30-60 mins 
before the procedure**
Advice not given
Recommended Antibiotic Prophylaxis Regimen for those Allergic to Penicillin
Clindamycin 600mg orally 30-60 
mins before the procedure**
Clindamycin 600mg orally 30-60 
mins before the procedure**
Advice not given
CHD congenital heart disease, MVP mitral valve prolapse, ASD atrial septal defect, VSD ventricular septal defect
* Excluding local anaesthetic injections through uninfected tissue (see original guidelines for all other exclusions)
** Please see original guidelines for children’s doses and parenteral and other alternative regimens
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The Move to Restrict the Number of Individuals
Who Should Receive Antibiotic Prophylaxis
In 2006, BSAC published new AP recommendations for the
UK [35] and, supported by a Cochrane review [36], argued
that there was no evidence to support the use of AP during
invasive dental procedures. Nonetheless, they stopped short of
recommending cessation of AP for invasive dental procedures
and instead recommended it should only be given to those at
high risk of IE and its complications (those with a previous
history of IE, mechanical or biological prosthetic valves or a
surgically constructed systemic or pulmonary shunt or con-
duit). However, for those undergoing a broad range of inva-
sive gastrointestinal, genitourinary, gynaecological and respi-
ratory procedures, they continued to recommend AP for those
at both moderate and high risks of IE.
The suggestion that AP for invasive dental procedures
should be restricted to those at highest risk caused outrage
on the part of UK cardiologists [37, 38], and the topic was
referred to the newly formed National Institute for Health and
Care Excellence (NICE). In March 2008, the NICE revealed
the outcome of its review, and to the disbelief and shock of
many cardiologists and cardiothoracic surgeons, recommend-
ed the complete cessation (for all procedures and all patients)
of AP to prevent IE [39]. For dentists, this recommendation
simplified patient management, removed a serious cause for
concern and was rapidly and widely adopted [40, 41]. The
main reasons given by the NICE for this recommendation
were the lack of evidence to support the effectiveness of AP
[39] and the results of their health economic analysis that
concluded AP was not cost-effective [42].
Whilst the NICE guideline reviewwas underway, the AHA
announced the outcome of their latest guideline review, in
2007 [43]. Like BSAC, they recommended that the use of
AP should be restricted to those at the highest risk of IE or
its complications (Table 1) and that AP should cease for those
at moderate risk (e.g. those with native or rheumatic valve
disease). Beyond the BSAC recommendations, they also ad-
vised that AP should cease for many non-dental invasive pro-
cedures (including all genitourinary and gastrointestinal
procedures).
These recommendations were closely mirrored in the 2009
ESC guidelines that restrictedAP to those at the highest risk of
IE. The AHA or ESC guidelines have been widely adopted
around the world (excluding Sweden who have adopted the
UK NICE guidelines).
The Impact of Changing Antibiotic Prophylaxis
Guidelines
The best evidence for efficacy of AP would come from a
randomised placebo controlled trial (RCT). Unfortunately,
such a trial has never been performed and is unlikely in the
foreseeable future due to cost and logistic reasons. Many hun-
dreds of thousands of individuals at risk of IE would need to
be randomised to placebo or prophylaxis to have sufficient
statistical power to detect an effect [44]. A further barrier is
the ethical concern of randomising individuals at risk of IE to
placebo, particularly in countries where AP is the current stan-
dard of care [44].
Nevertheless, several recent observational studies have
attempted to determine whether recent changes in AP guide-
lines have altered the incidence of IE. In 2012, Duval et al.
reported three 1-year population-based studies from three
French regions [45] assessing the impact of the 2002 French
guidelines which recommended that AP should continue in
those at high risk but was optional in those at lower risk
[46]. Comparing two periods before the guideline change
(1991 and 1999) with a period after (2008), they found no
significant change in the incidence of IE (or oral streptococci
IE). However, there were no prescribing data to demonstrate
actual AP prescribing and the 2004 ESC guidelines may have
influenced AP prescribing in France by 2008.
A number of studies have examined the impact of the 2007
AHA guidelines. Rogers and Schiller reported no increase in
the number of IE admissions at a San Francisco Medical
Center 9 months after the guideline change [47], and
Desimone et al. examined Olmsted County data from 1999
to 2010 and concluded there was no increase in the incidence
of viridans group streptococcal IE [48]. However, the small
sample size and short follow-up period of both studies need
consideration. Bor et al. used 1998–2009 data from the
National Inpatient Sample to assess a broader cohort of pa-
tients but found no significant increase in the incidence of IE
(overall or secondary to streptococcal infection) although the
follow-up period was short. [49] Indeed, in a subsequent study
of the same data set with 4 years follow-up, Pant et al. iden-
tified an increase in the incidence of streptococcal IE [50].
Although there are a number of limitations to this study, in-
cluding the lack of any AP prescribing data [49], the authors
speculated that the increase in streptococcal IE could result
from decreased use of AP following the 2007 AHA guide-
lines. Another study by Pasquali et al. used the Pediatric
Health Information Systems Database to study the effect of
the 2007 guidelines on the incidence of IE between 2003 and
2010 in children age <18 years admitted to 37 US children’s
hospitals and found no significant change in the incidence of
total or streptococcal IE [51]. Similarly, Bikdeli et al. found no
significant effect in a study of over 65 year olds with a prin-
cipal or secondary diagnosis of IE from 1999 to 2010 using
Medicare Inpatient Standard Analytic Files [52].
However, all of these studies are limited by one or more of
the following shortcomings: small sample size, short follow-
up period, sub-population studies with different risk factors or
exposure to invasive dental procedures compared to the
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general population, use of secondary as well as primary IE
diagnoses, difficulties in accurately identifying IE caused by
oral viridans group streptococci and a lack of data on AP
prescribing. Thus, it is very difficult to draw firm conclusions
from any one or a combination of these studies [49].
In 2016, Mackie et al. used the Canadian Institute for
Health Information Discharge Abstract Database to identify
primary diagnoses of IE in Canada between 2002 and 2013
[53••]. Although there was no increase in the overall incidence
of IE following the AHA guidelines, sub-analysis demonstrat-
ed that the declining incidence of streptococcal IE was re-
versed after 2007. A similar pattern was also noted in individ-
uals at moderate risk of IE (the group for whom AP ceased in
2007) [54, 55].
The 2008 NICE guidelines recommended the complete
cessation of AP in the UK where previously it had been rec-
ommended for those at moderate and high risk of IE. A 2011
study by Thornhill et al. of the 53 million population of
England identified no significant increase in the incidence of
IE in the subsequent 2 years despite a 78.6% fall in AP pre-
scribing [41]. Definitive conclusions were not possible how-
ever owing to the short follow-up period and residual 21.4%
level of AP prescribing [56, 57]. The study was therefore
repeated with 5 years follow-up demonstrating a further de-
crease in AP prescribing (overall 88% fall) and a significant
increase in the incidence of IE in the period following intro-
duction of the NICE guidelines (p<0.0001) which exceeded
pre-existing trends [58••]. Thus, by March 2013 in England
alone, there were an extra 419 IE cases per year than expected
(p<0.0001; 95% CI 117–743). These observational data do
not prove that the fall in AP prescribing caused the increase in
IE although a careful search for alternative causes has not
identified a satisfactory explanation. Moreover, the study
identified a significant increase in the incidence of IE in both
high-risk (p<0.001) and lower-risk (p=0.01) groups, raising
the possibility that AP may be of some benefit to those at
moderate risk of IE.
Recent Guideline Reviews
This spate of epidemiological evidence led the NICE to re-
view its guidance at the same time as a scheduled review of
ESC practice guidelines for the prevention, investigation and
management of IE. Meanwhile, the AHA has announced ap-
proval for a review, but this it is not expected before 2018.
In September 2015, the NICE and the ESC announced their
updated guidance having evaluated exactly the same evi-
dence—the results could not have been more different. The
NICE deemed that there was insufficient evidence to warrant
any change to their existing guidance and continued to recom-
mend against AP [59•]. In contrast, the ESC concluded that
“the weight of evidence and opinion is in favour of the
efficacy and usefulness of AP in preventing IE in those at
high-risk”. And that “AP should be given before invasive
dental procedures to all patients at high-risk of IE”. [60••].
Furthermore, the ESC guideline committee considered but
rejected the 2008 NICE guidance not to recommend AP on
account of (a) the remaining uncertainties regarding estima-
tions of the risk of IE; (b) the worse prognosis of IE in high-
risk patients (particularly those with prosthetic valves); and (c)
the fact that high-risk patients account for a very small pro-
portion of those previously covered by AP, thereby reducing
the number exposed to any possible harmful adverse effects.
The ESC recommended AP only for high-risk individuals
undergoing high-risk invasive dental procedures and the AP
regimen remained unchanged from 2009 [60••]. Its guidance
therefore remains similar to that of the AHA (Table 1).
How Can the ESC and NICE Differ So Much
in Their Interpretation of the Same Evidence?
The ESC and AHA guideline committees consist of clinicians
with relevant clinical expertise, including cardiologists, car-
diothoracic surgeons, infectious disease experts and dentists.
In both cases, the relevant professional bodies reviewed the
guidance before submission to international peer reviewed
journals where they were subjected to further external review.
Both committees reviewed the available evidence (including
animal and observational studies) before reaching their
conclusions.
In contrast, the primary purpose of NICE is to evaluate the
cost-effectiveness of drugs and technologies for use in the UK
National Health Service. The AP review was performed by a 14-
member standing committee that deals with a variety of different
guidelines but has no particular expertise in IE. NICE review
committees work to set protocols, largely designed for the eval-
uation of treatments for which RCT data are available. Animal
studies are automatically excluded and even the best observation-
al studies are deemed of “low quality” [59•].
Following their initial decision, the NICE came under con-
siderable pressure from academics, cardiologists, dentists, pa-
tients and politicians to reconsider their view. As a conse-
quence, their guidance was subtly changed in July 2016 to
state that “AP against IE is not recommended routinely for
people undergoing dental procedures”. The addition of the
word “routinely” indicates that AP may be appropriate in in-
dividual cases [61•] and, in the absence of clear guidance
concerning which individuals should receive AP, which dental
procedures should be covered and what AP regimes should be
used, places the responsibility for decisions concerning the
use of AP with cardiologists and dentists. In this situation, it
has been suggested by some that clinicians in the UK should
follow recommendations based on the 2015 ESC guidelines
[60••, 61•, 62].
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The Costs and Benefits of Antibiotic Prophylaxis
In the absence of RCT data, the benefits of AP are hard to
quantify, although guideline committees implicitly acknowl-
edge that there is a benefit in recommending AP for certain
patient groups. If caused by the fall in AP prescribing, the
increase in incidence of IE identified in the UK following
introduction of the NICE guideline in 2008 suggests that
277 (95% CI 156–1217) prescriptions of AP are needed to
prevent one case of IE and provides a reasonable estimate of
AP effectiveness [58••]. The main potential problems with AP
are (i) risk of adverse drug reactions, (ii) cost and (iii) risk of
promoting antibiotic resistance.
A recent study [63••] found no recorded cases of death
associated with amoxicillin AP (single 3 g oral dose) and
a very low rate of non-fatal adverse reactions (22.6/mil-
lion prescriptions). The incidence of adverse reactions
with clindamycin AP (single 600 mg oral dose) was also
low but higher than anticipated with 13 and 149 fatal and
non-fatal adverse reactions/million prescriptions, respec-
tively, nearly all of which related to Clostridium difficile
infections. These data demonstrate a very high level of
safety of amoxicillin AP in individuals with no history
of allergy and suggest that an alternative to clindamycin
(or no AP at all) should be considered for those who are
allergic to penicillins. Unfortunately, these data were un-
available for the recent NICE and ESC guideline reviews
but may be considered in future guideline reviews.
The cost of AP is modest [64] whereas the cost of treating
IE is very high. However, the two most critical elements in
evaluating the cost-effectiveness of AP are the incidence of
adverse drug reactions and the efficacy of AP. Lack of cost-
effectiveness was one of the reasons given by the NICE in
2008 for recommending the cessation of AP in the UK [39].
However, their cost-effectiveness analysis assumed little or no
effectiveness for AP and used historical data (including long
term parenteral penicillin use) which over-estimated the rate
of adverse drug reactions [42, 65]. Perhaps not surprisingly,
they concluded that AP was not cost-effective. In contrast, a
recent health-economic study using contemporary efficacy
and adverse reaction data found that AP was highly cost-
effective (and even cost saving) [66].
Unfortunately, there are no data concerning the risk of in-
ducing antibiotic resistance associated with AP. However,
most concern relates to the use of lower dose therapeutic an-
tibiotic regimens over several days and not to use of a single
high dose of a bactericidal antibiotic, such as amoxicillin.
Conclusions
The concept of AP to prevent IE has changed considerably
since it was first formally introduced in the AHA guidelines of
1955 [21]. Dose and administration regimens have become
simpler and shorter, and the number of individuals and proce-
dures where AP is recommended has significantly reduced.
Virtually all guideline committees around the world recom-
mend AP for high-risk individuals undergoing high-risk inva-
sive dental procedures (Table 1).
In the absence of RCT data to confirm the effectiveness of
AP, observational studies are vital to determine the impact of
guideline recommendations on the incidence of IE.
Unfortunately, most observational studies are underpowered
or have other methodological limitations. Most studies have
shown little, if any, adverse impact of limiting AP to those at
high risk of IE. However, some of the best designed and con-
ducted studies suggest that complete cessation of AP may
increase the incidence of IE [50, 53••, 54, 55, 58••]. More
focussed and better-powered studies should eventually clarify
this longstanding issue and provide better data concerning the
risk of adverse drug reactions, cost-effectiveness of AP and
the particular populations (if any) to whom AP should be
targeted. At present, the stance currently adopted by most
guideline committees limiting AP use to those at highest risk
seems pragmatic and appropriate.
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